Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label, Multiple-dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Pacritinib in Subjects With Varying Degrees of Hepatic Impairment Compared to Healthy Subjects

NCT05552183 is registered in ClinicalTrials.gov with CTI BioPharma as lead sponsor.

NCT NCT05552183
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05552183 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label, Multiple-dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Pacritinib in Subjects With Varying Degrees of Hepatic Impairment Compared to Healthy Subjects
Lead sponsor
CTI BioPharma
Phase
Phase 1
Overall status
Completed
Start date
December 12, 2022
Completion date
June 10, 2024
Enrollment
29 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic impairment